Corbett Stephanie Mallow, Montoya Isaac D, Moore Frederick A
University of Houston College of Pharmacy, Department of Pharmacy, Methodist Hospital, Houston, TX, USA.
Pharmacotherapy. 2008 Feb;28(2):250-8. doi: 10.1592/phco.28.2.250.
The Institute of Medicine has identified adverse drug events as factors that significantly contribute to increased patient morbidity and mortality. As critically ill patients receive numerous drugs to treat a multitude of complicated health problems, they are at high risk for adverse drug events. Sedation is often a key requirement for the optimal management of critical illness, and propofol, a common sedative, has many desirable characteristics that make it the ideal agent in numerous circumstances. However, over the last decade, increasing numbers of reports have described a potentially fatal adverse effect called propofol-related infusion syndrome. Whether this adverse drug event is preventable is unclear, but recommendations have been proposed to minimize the potential for development of this syndrome. Research is under way to collect data on the use of propofol in intensive care units and on its prevalence.
医学研究所已将药物不良事件确定为导致患者发病率和死亡率上升的重要因素。由于重症患者需要使用多种药物来治疗众多复杂的健康问题，他们发生药物不良事件的风险很高。镇静常常是重症优化管理的关键要求，丙泊酚作为一种常用镇静剂，具有许多理想特性，使其在众多情况下成为理想药物。然而，在过去十年中，越来越多的报告描述了一种名为丙泊酚输注综合征的潜在致命不良反应。这种药物不良事件是否可预防尚不清楚，但已提出相关建议以尽量降低该综合征发生的可能性。目前正在开展研究，以收集重症监护病房中丙泊酚使用情况及其发生率的数据。
